Cystoscopy is Mandatory for This Patient
This 85-year-old man with painless hematuria requires cystoscopy regardless of the negative CT findings, as bladder cancer remains the primary concern and CT imaging cannot reliably exclude urothelial malignancy. 1
Diagnostic Work-Up
Cystoscopy is Non-Negotiable
- Cystoscopy remains the gold standard for detecting bladder cancer in patients presenting with hematuria, with sensitivity ranging from 47-100% and specificity from 93.4-100%. 1
- The CT showing no urothelial lesion does not eliminate the need for cystoscopy—imaging has inferior diagnostic accuracy compared to direct visualization for bladder tumors. 1, 2
- Painless visible hematuria carries a 9% risk of bladder cancer, making cystoscopy essential despite the patient's age. 1
Additional Initial Evaluation
- Obtain International Prostate Symptom Score (IPSS) to quantify lower urinary tract symptoms and assess whether the enlarged prostate is contributing to symptomatology. 3
- Perform urinalysis (already done given hematuria detection) and consider post-void residual (PVR) measurement to assess for urinary retention from prostatic obstruction. 3
- Do NOT order voided urinary cytology—it lacks sufficient sensitivity to obviate cystoscopy and adds unnecessary cost without changing management. 4
Management Strategy
Address the Hematuria First
The enlarged prostate with mass effect could be contributing to the hematuria through vascular congestion of the hyperplastic gland. 5, 6
If cystoscopy rules out bladder cancer:
- Consider initiating a 5-alpha reductase inhibitor (finasteride or dutasteride) specifically to control prostatic bleeding. 5, 6
- Studies show finasteride effectively suppresses hematuria from benign prostatic hyperplasia in 83% of patients (20 of 24 treated patients had complete resolution). 6
- This approach is particularly appropriate given the patient's age and the risks of surgical intervention. 5
Manage BPH-Related LUTS (If Present)
- If the patient has bothersome lower urinary tract symptoms (assess with IPSS), initiate an alpha-blocker (e.g., tamsulosin, alfuzosin) as first-line therapy. 3
- Given the enlarged prostate (likely >30cc based on "mass effect" description), add a 5-alpha reductase inhibitor to the alpha-blocker for combination therapy. 3
- If the patient has concurrent erectile dysfunction, consider a phosphodiesterase-5 inhibitor (PDE5i) as initial monotherapy or in combination. 3
- Re-evaluate at 4-12 weeks to assess symptom response using repeat IPSS, and consider PVR and uroflowmetry. 3
Critical Pitfalls to Avoid
Do Not Attribute Hematuria to BPH Without Excluding Malignancy
- The enlarged prostate is a convenient explanation, but bladder cancer must be ruled out first via cystoscopy—this is non-negotiable in an 85-year-old with gross hematuria. 1, 2
- Even if BPH is ultimately the cause of bleeding, you cannot make this diagnosis of exclusion without direct bladder visualization. 5
The 3mm Renal Stone is a Red Herring
- A 3mm non-obstructing upper pole stone does not cause hematuria in the absence of acute obstruction or passage. 7
- Do not be distracted by this incidental finding—it requires no intervention or follow-up. 7
Age is Not a Contraindication to Cystoscopy
- Flexible cystoscopy is an outpatient procedure with local anesthesia that is well-tolerated even in elderly patients. 1
- The risk of missing bladder cancer far outweighs the minimal procedural risk. 1
Follow-Up Considerations
- If hematuria persists despite 5-alpha reductase inhibitor therapy (after malignancy exclusion), consider transurethral resection of the prostate (TURP) for definitive management of prostatic bleeding. 5, 6
- Monitor for 5-ARI side effects including erectile dysfunction and gynecomastia (occurred in 2 of 24 patients in one series). 5
- Do not repeat hematuria investigations if bleeding recurs after negative initial workup—the yield is extremely low and exposes the patient to unnecessary radiation and invasive testing. 5